This Article Full Text Full Text (PDF) Erratum (v18,p2644) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaufman, D. Articles by Stadler, W. Search for Related Content PubMed PubMed Citation Articles by Kaufman, D. Articles by Stadler, W.

Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer

From the Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston, MA; University of Southern California–Norris Comprehensive Cancer Center, Los Angeles, CA; Johns Hopkins University, Baltimore, MD; Roswell Park Cancer Institute, Buffalo, NY; Vanderbilt University School of Medicine, Nashville, TN; Cancer Institute of New Jersey, New Brunswick, NJ; University of Chicago and Northwestern University Medical School, Chicago, IL; and Eli Lilly and Company, Indianapolis, IN.

Address reprint requests to Donald Kaufman, MD, Massachusetts General Hospital, 1 Hawthorne Place, Room 107, Boston, MA 02114.

PURPOSE: To assess the activity and toxicity of the combination of gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with metastatic urothelial cancer.

PATIENTS AND METHODS: Forty-six patients with measurable stage IV carcinoma of the urothelium were enrolled onto this trial. Gemcitabine 1,000 mg/m² was administered intravenously for 30 to 60 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after gemcitabine on day 1 of each cycle. The first 11 patients received an initial cisplatin dose of 100 mg/m². Due to the hematologic toxicity observed in several of these patients, the dose was reduced to 75 mg/m² in the remaining 35 patients. Patients were treated with six cycles, unless disease progression or severe toxicity necessitated earlier discontinuation.

RESULTS: Ten of the 46 patients achieved a complete response and nine showed a partial response. The overall response rate was 41%. The median time to treatment failure was 5.5 months. The median survival was 14.3 months, and the 1-year survival probability was 54%. Most of the toxicities were hematologic and, in general, easily manageable.

CONCLUSION: Gemcitabine plus cisplatin is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and has an acceptable clinical safety profile. Studies are under way to further define the place of gemcitabine in combination with other chemotherapeutic agents in the treatment of metastatic urothelial cancer.

This article has been cited by other articles:

				J. A. Garcia and R. Dreicer Systemic Chemotherapy for Advanced Bladder Cancer: Update and Controversies J. Clin. Oncol., December 10, 2006; 24(35): 5545 - 5551. [Abstract] [Full Text] [PDF]

				I Boukovinas, N Androulakis, L Vamvakas, P Papakotoulas, N Ziras, A Polyzos, A Kalykaki, A Kotsakis, N Xenidis, I Gioulmbasanis, et al. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group Ann. Onc., November 1, 2006; 17(11): 1687 - 1692. [Abstract] [Full Text] [PDF]

				A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann. Onc., April 1, 2006; 17(4): 553 - 561. [Abstract] [Full Text] [PDF]

				H. von der Maase, L. Sengelov, J. T. Roberts, S. Ricci, L. Dogliotti, T. Oliver, M. J. Moore, A. Zimmermann, and M. Arning Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer J. Clin. Oncol., July 20, 2005; 23(21): 4602 - 4608. [Abstract] [Full Text] [PDF]

				E. Kent, H. Sandler, J. Montie, C. Lee, J. Herman, P. Esper, J. Fardig, and D. C. Smith Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial J. Clin. Oncol., July 1, 2004; 22(13): 2540 - 2545. [Abstract] [Full Text] [PDF]

				L. C. Pagliaro, R. E. Millikan, S.-M. Tu, D. Williams, D. Daliani, C. N. Papandreou, and C. J. Logothetis Cisplatin, Gemcitabine, and Ifosfamide As Weekly Therapy: A Feasibility and Phase II Study of Salvage Treatment for Advanced Transitional-Cell Carcinoma J. Clin. Oncol., July 1, 2002; 20(13): 2965 - 2970. [Abstract] [Full Text] [PDF]

				M. Hussain, U. Vaishampayan, W. Du, B. Redman, and D. C. Smith Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer J. Clin. Oncol., May 1, 2001; 19(9): 2527 - 2533. [Abstract] [Full Text] [PDF]

				D. S. Kaufman, K. A. Winter, W. U. Shipley, N. M. Heney, M. P. Chetner, L. Souhami, R. A. Zlotecki, W. T. Sause, and L. D. True The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response Oncologist, December 1, 2000; 5(6): 471 - 476. [Abstract] [Full Text]

				H. von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, M.J. Moore, I. Bodrogi, P. Albers, A. Knuth, C.M. Lippert, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study J. Clin. Oncol., September 17, 2000; 18(17): 3068 - 3077. [Abstract] [Full Text] [PDF]